Elicio Therapeutics is a clinical-stage biotechnology company developing potent immunotherapies using its proprietary Amphiphile vaccine platform, which delivers immunogens directly to the lymph nodes to amplify immune responses against cancer. Its lead program ELI-002 is a KRAS-targeted cancer vaccine being studied in mKRAS-positive pancreatic ductal adenocarcinoma and other solid tumors. In June 2026 the Phase 2 AMPLIFY-201 trial missed its primary endpoint, sending shares down sharply, though the company said it will still advance to a Phase 3 study based on a subpopulation signal.
Company Info
Upcoming Milestones & Key Dates
Detailed AMPLIFY-201 Phase 2 subpopulation analysis and Phase 3 design
Investor update on strategic pipeline priorities and cash runway
Clinical Development Pipeline
Recent News
Elicio Therapeutics' KRAS-targeted cancer vaccine failed to meet its primary Phase 2 endpoint in metastatic pancreatic cancer, sending shares down more than 60% and forcing a strategic review of the platform.
Elicio Therapeutics' KRAS-targeted cancer vaccine missed its Phase 2 primary endpoint in pancreatic cancer, cratering the stock, but the company said it will still advance the program to a Phase 3 trial based on a subpopulation signal.
Leadership Team
Chief Executive Officer
Chief Medical Officer
Acting Chief Medical Officer
Careers & Job Openings